Comparison of tapentadol PR and oxycodone/naloxone PR

• Register: EUCTR
• Last refreshed on: 31 March 2014
• Main ID: EUCTR2012-002943-11-AT
• Date of registration: 08/04/2013
• Prospective Registration: Yes
• Primary sponsor: Grünenthal GmbH
• Public title: Comparison of tapentadol PR and oxycodone/naloxone PR
• Scientific title: Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neuropathic pain component.
• Date of first enrolment: 23/07/2013
• Target sample size: 240
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002943-11
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2

Countries of recruitment

Austria, Germany, Italy, Spain

Contacts

• Name: GRT Trial Information Desk
• Affiliation: Grünenthal GmbH

• Name: GRT Trial Information Desk
• Affiliation: Grünenthal GmbH

Key inclusion & exclusion criteria

Inclusion criteria:
1. Informed consent signed.
2. Male or female subject =18 years of age.
3. Women of childbearing potential must have a negative pregnancy test at the Enrollment Visit.
4. Women of childbearing potential must practice medically acceptable
methods of birth control during the trial.
5. Subjects must be appropriately communicative and able to differentiate with regard to location and intensity of the pain, and to complete the questionnaires used in this trial.
6. Subjects must have a diagnosis of chronic low back pain; chronic pain defined as pain lasting for at least 3 months prior to enrollment.
7. Subject’s pain must require a strong analgesic (defined as WHO Step III) as judged by the investigator.
8. Subjects who require a washout of co-analgesics at enrollment must have an average pain score (NRS-3) of 5 points or higher.
Subjects who do not require a washout of co-analgesics at enrollment must have an average pain intensity score (NRS-3) of 6 points or higher.
9. The painDETECT diagnostic screening questionnaire must be either “positive” (= score of 19 to 38 inclusive) or “unclear” (= score of 13 to 18 inclusive) or If the subject is being treated with a stable regimen of centrally acting co-analgesics, a “negative” painDETECT scorescore (but 9 points or higher) at the Enrollment Visit will be acceptable
Inclusion criteria at the Randomization Visit
10. Subjects must have an average pain intensity score (NRS-3) of 6 points or higher.
11. Subjects must score either “positive” (= score of 19 to 38 inclusive) or “unclear” (= score of 13 to 18 inclusive) on the painDETECT diagnostic screening questionnaire.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 240
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 240

Exclusion criteria:
1. Presence of a clinically significant disease or clinical laboratory values that in the investigator’s opinion may affect effectiveness, quality of life, or safety/tolerability assessments
2. Presences of active systemic or local infections that may, in the opinion of the investigator, affect the effectiveness, quality of life, or safety/tolerability assessments.
3. Employees of the investigator or trial site, with direct involvement in this trial or other trials under the direction of the investigator or trial site, as well as family members of employees of the investigator.
4. Participation in another trial concurrently, or within 4 weeks prior to the Enrollment Visit.
5. Known to or suspected of not being able to comply with the protocol and/or appropriate use of the IMPs.
6. Any painful procedures (e.g., major surgery) scheduled during the trial duration (Enrollment Visit until Final Evaluation Visit) that may, in the opinion of the investigator, affect the effectiveness, quality of life, or safety assessments.
7. Pending litigation or application for insurance/governmental benefits due to chronic pain or disability and/or if the granted benefits might be influenced by a successful participation in the trial.
8. Low back pain caused by cancer and/or metastatic diseases.
9. History of alcohol or drug abuse, or suspicion thereof in the investigator’s judgment.
10. Presence of concomitant autoimmune inflammatory conditions.
11. Subjects with acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic active substances.
12. Subjects with severe renal impairment, i.e., estimated glomerular filtration rate less than 30 mL/min (according to the National Kidney Foundation 2002).
13. Known history of clinical laboratory values or current clinical laboratory values reflecting moderately or severely impaired hepatic function.
14. History of seizure disorder or epilepsy.
15. Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm (including brain metastases if present at the Enrollment Visit). Severe traumatic brain injury within 15 years (consisting of 1 or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting more than 24 hours) or residual sequelae.
16. Pregnant or breast-feeding women.
17. Severe respiratory depression with hypoxia and/or hypercapnia, acute or severe bronchial asthma or severe chronic obstructive pulmonary disease.
18. Presence or suspicion of paralytic ileus.
19. Subjects with severe cardiac impairment, e.g., New York Heart Association class >3, myocardial infarction less than 6 months prior to the Enrollment Visit, and/or unstable angina pectoris and/or cor pulmonale.
20. Subjects with known history of rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.
21. History of allergy or hypersensitivity to tapentadol, oxycodone, naloxone, and their formulations.
22. Subjects with acute biliary obstruction or acute pancreatitis.
23. Subjects with hypothyroidism (including myxedema) or Addison’s disease.
24. Subjects taking any prohibited concomitant medication.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Severe chronic low back pain with a neuropathic pain component
MedDRA version: 14.1 Level: LLT Classification code 10054095 Term: Neuropathic pain System Organ Class: 100000004852
MedDRA version: 14.1 Level: LLT Classification code 10024891 Term: Low back pain System Organ Class: 100000004859

Intervention(s)

Trade Name: Palexia retard 50 mg
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Tapentadol hydrochloride
CAS Number: 175591-09-0
Current Sponsor code: CG5503
Other descriptive name: TAPENTADOL HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-

Trade Name: Palexia retard 100 mg
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Tapentadol hydrochloride
CAS Number: 175591-09-0
Current Sponsor code: CG5503
Other descriptive name: TAPENTADOL HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-

Trade Name: Targin 10 mg / 5 mg Retardtabletten
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: oxycodone hydrochloride
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
INN or Proposed INN: naloxone hydrochloride dihydrate
CAS Number: 51481-60-8
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-

Trade Name: Targin 20 mg / 10 Retardtabletten
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: oxycodone hydrochloride
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
INN or Proposed INN: naloxone hydrochloride dihydrate
CAS Number: 51481-60-8
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-

Trade Name: Targin 40 mg / 20 Retardtabletten
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: oxycodone hydrochloride
CAS Number: 124-90-3
Other descriptive name: OXYCODONE HYDROCHLORIDE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
INN or Proposed INN: naloxone hy

Primary Outcome(s)

Primary end point(s): The first primary endpoint of this trial is defined as the change in the average pain intensity core during the last 3 days (numerical rating scale [NRS]-3 pain intensity scores) from the Randomization Visit to the end of continuation (Final Evaluation Visit, 12 weeks after the Randomization Visit).
The second primary endpoint will be the change in the patient assessment of constipation symptoms (PAC-SYM) total score from the Randomization Visit to the end of continuation (Final Evaluation Visit, 12 weeks after the Randomization Visit).

Main Objective: The primary objective is to evaluate the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neuropathic pain component.

Secondary Objective: • To evaluate and compare tolerability profiles of tapentadol PR versus oxycodone/naloxone PR during the titration period and throughout the trial with a focus on gastrointestinal and central nervous system-related tolerability.
• To evaluate the impact of tapentadol PR and oxycodone/naloxone PR on neuropathic pain-related symptoms.
• To compare the impact on function and quality of life parameters between tapentadol PR and oxycodone/naloxone PR in subjects with severe chronic low back pain.
• To compare effectiveness in terms of reduction of pain intensity between tapentadol PR and oxycodone/naloxone PR during titration as well as throughout the entire treatment period in the trial.
• To investigate the impact of tapentadol PR versus oxycodone/naloxone PR on serum levels of sexual hormones

Timepoint(s) of evaluation of this end point: Final evaluation visit

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: 1. At respective site visits during the early treatment phase
2. At respective site visits as specified in the protocol

Secondary end point(s): 1.Comparison of relevant parameters related to the evaluation of early gastrointestinal treatment emergent adverse events (TEAEs) under tapentadol PR and oxycodone/naloxone PR.
2.
• Pain intensity scores on an 11-point NRS-3.
• PainDETECT scores.
• EuroQol-5 Dimension (EQ-5D) scores.
• NRS-3 pain intensity scores for pain radiating towards or into the leg.
• Worst pain (11-point NRS) during the last 24 hours prior to the assessment visit.
• Patient global impression of change (PGIC).
• Clinician’s global impression of change (CGIC).
• Neuropathic pain symptom inventory (NPSI).
• Short Form-12® health survey (SF-12) scores.
• Hospital anxiety and depression scale (HADS).
• Sleep evaluation score.
• Work productivity and activity impairment questionnaire (WPAI).
• Adverse events
• Overall discontinuation rates related to treatment arms
• Time to discontinuation from treatment (due to any reason).
• Time to discontinuation from treatment (due to adverse events).
• PAC-SYM.
• Vital signs.
• Clinical laboratory values.
• Medication used to treat the adverse events related to the IMPs.
• Hormone serum levels under treatment with IMPs:
• Aging males’ symptoms questionnaire

Secondary ID(s)

2012-002943-11-DE

KF5503/60

Source(s) of Monetary Support

Grünenthal GmbH